BioSpace News Archive

Adimab, LLC, the global leader in the discovery and optimization of fully human monoclonal and bispecific antibodies, announced an expanded offering of proprietary technologies to aid the development of antibody and multispecific therapeutic modalities.

Titan Medical Inc. announced that it has received payment from Medtronic plc after successfully achieving the final milestone under the development and license agreement announced on January 4, 2022.

Zero Gravity Solutions, Inc. (“ZGSI” or the “Company”) (Pink Sheets: ZGSI), an agricultural biotechnology company, announced that the International Journal of Biochemistry Research and Review has published a peer reviewed research paper outlining the mechanism by which the Company’s technology activates plants’ innate disease defenses.

Southern California cord blood therapeutics company StemCyte Inc. is announcing successful preliminary results for Phase I of the company’s clinical trial for treating acute cerebral stroke using monocytes from allogeneic human umbilical cord blood (hUCB).

BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that the US Patent Office had allowed a utility patent covering its PURE EP™ noise-filtering technology.

The translation of research into the development of innovative and life-saving microbial therapies is set to transform in Australia through a partnership between Hudson Institute of Medical Research and BiomeBank, a clinical stage microbiome therapeutics company.

Accuray Incorporated reported financial results for the second quarter of fiscal 2022 ended December 31, 2021.

Zymeworks Inc., a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, announced that it has commenced an underwritten public offering of its common shares and, in lieu of common shares to certain investors, pre-funded warrants to purchase its common shares.

NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company’’) (Paris:NANO) (NASDAQ:NBTX), today announced the publication of new preclinical immunotherapy data for novel, potentially solid tumor- and therapeutic combination-agnostic radioenhancer NBTXR3 in the Journal of Nanobiotechnology.

Edwards Lifesciences reported financial results for the quarter ended December 31, 2021.